Cannabinoid CB1 receptors have been a potential target for nonopioid-based pain treatment, but actually targeting the pathway has been hindered by issues with tolerance and unwanted CNS side effects.

Read the paper: A cryptic pocket in CB1 drives peripheral and functional selectivity Many important drug targets are G-protein-coupled receptors (GPCRs), including those activated by blockbuster ...

The majority of CB1 receptors in the brain act on neurons, but some of these triggers are also found on non-neuronal cells called astrocytes. Astrocytes are the most common cell in the central nervous ...

Dror. VIP36’s structure combines the potent CB1 agonist MDMB-Fubinaca with a tail that has a guanidinium group, which is positively charged in the body. That charge prevents it from crossing the ...

IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer’s - POTOMAC, MD / ACCESS Newswire / March ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the ...

IGC Pharma (IGC) announced additional interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for ...

IGC-AD1's mechanism of action involves working as a partial cannabinoid receptor 1 (CB1) agonist with anti-neuroinflammatory properties, which may influence neuroinflammation, oxidative stress, and ...